Nanozyme Loaded with Resveratrol for Osteoarthritis Therapy via Wnt/β-Catenin Pathway and Microenvironment Regulation
ACS Applied Materials & Interfaces · 2026
DOI: 10.1021/acsami.6c05934 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2026. Verfasst von Tianyu Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation, The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University, Xuzhou, Jiangsu221018, China. Hauptthemen laut MEDLINE: Resveratrol, Osteoarthritis, Wnt Signaling Pathway, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, Southwest Medical University, Science and Technology Strategic Cooperation Programs of Luzhou Municipal People's Government and Southwest Medical University.
Abstract (Originalsprache)
Osteoarthritis (OA) is a chronic degenerative disease causing bone and cartilage deterioration, joint deformity, and functional loss. The initiation and progression of OA are primarily driven by oxidative stress and the abnormal activation of the Wnt/β-catenin signaling pathway. This study involved loading Resveratrol (Res) and platinum (Pt) nanozymes, which exhibit superoxide dismutase (SOD) and catalase (CAT), onto a metal-organic framework (MOF) due to its distinctive porosity and high loading capacity. The system was further modified with hyaluronic acid (HA) to synthesize Pt-MOF/Res@HA (PMRH) nanoparticles. The PMRH nanoparticles improve early OA prevention and treatment by concurrently inhibiting the Wnt/β-catenin signaling pathway and eliminating reactive oxygen species (ROS). Experimental results, both in vitro and in vivo, indicate that PMRH nanoparticles efficiently scavenge ROS within the OA microenvironment. The PMRH nanoparticles inhibit the overactive Wnt/β-catenin signaling pathway in chondrocytes affected by osteoarthritis. This dual-target approach, which addresses oxidative stress and inhibits the Wnt/β-catenin signaling pathway, shows promising therapeutic potential for OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rehabilitation, The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University, Xuzhou, Jiangsu221018, China.
- Department of Rehabilitation, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu221004, China.
- Department of Orthopedics, The People's Hospital of Rongchang District, Chongqing402460, China.
- The Affiliated Pizhou Hospital of Xuzhou Medical University, Pizhou, Jiangsu221300, China.
- Department of Orthopedics, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan646000, China.
ORCID-Profile: Zheng Li
Förderung
- Science and Technology Department of Sichuan Province
- Southwest Medical University
- Science and Technology Strategic Cooperation Programs of Luzhou Municipal People's Government and Southwest Medical University
- Research Start-up Fund Project of the Affiliated Hospital of Southwest Medical University
Zitieren
APA
Xu, T., Zhong, J., Dai, C., Du, Y., Lyu, X., Ma, T., Zhang, P., Zhu, X., Li, Z., Quan, C., & Hu, Y. (2026). Nanozyme Loaded with Resveratrol for Osteoarthritis Therapy via Wnt/β-Catenin Pathway and Microenvironment Regulation. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.6c05934
Vancouver
Xu T, Zhong J, Dai C, Du Y, Lyu X, Ma T, et al. Nanozyme Loaded with Resveratrol for Osteoarthritis Therapy via Wnt/β-Catenin Pathway and Microenvironment Regulation. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.6c05934
BibTeX
@article{Xu2026,
author = {Xu, Tianyu and Zhong, Jun and Dai, Chengbai and Du, Yimin and Lyu, Xinzhe and Ma, Tian and Zhang, Panpan and Zhu, Xiaojia and Li, Zheng and Quan, Cheng and Hu, Yuting},
title = {Nanozyme Loaded with Resveratrol for Osteoarthritis Therapy via Wnt/β-Catenin Pathway and Microenvironment Regulation},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
doi = {10.1021/acsami.6c05934}
}
EUVIMED